Mabion
  • Company
    • About us
      • History
      • Leaderships
      • Team
      • EU grants
      • Requests for Proposal
      • Sustainability – ESG
      • Bussines strategy
      • Quality policy
      • Virtual Tour
    • Investors
      • Corporate documents
      • Shareholders and shares
      • Periodic reports
      • Current reports
      • Sustainability reports
      • Corporate governance at Mabion
      • Financial data
      • For Investors
      • Calendar
  • Resources
    • Science Hub
    • Press releases
    • News
    • Events
    • Media kit
  • Services
    • Process Development
    • Analytics 
    • Drug Substance Manufacturing
  • Contact
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • Science News
  • Resources

GMP

Preparing for Regulatory Audits with Reliable Quality Systems at Mabion

Preparing for Regulatory Audits at Mabion with Reliable Quality Systems

Biologics, EMA, FDA, GMP, Mabion, Regulatory
Meeting global regulatory standards in biologic drug manufacturing projects in Mabion Biologics

Meeting Global Regulatory Standards in Biologic Drug Manufacturing Projects

Biologics, EMA, FDA, GMP, Mabion, Manufacturing, Regulatory
cell line development

Tailoring Cell Line Development for Efficient Biologics Process Outcomes

Biologics, Drug development, GMP, Manufacturing
gmp biologics manufacturing

GMP Biologics Manufacturing in End-to-End Drug Development

Biologics, Drug development, GMP, Manufacturing
quality control of biologics

Quality Control of Biologics Ensuring Safety Through Aggregation Analysis

Analytics, Biologics, GMP, Proteins
ADC Manufacturing Services

ADC Manufacturing – A Comprehensive Guide to Drug Substance Manufacturing Services

Antibody-drug conjugates, GMP, Manufacturing
bioprocess scale up

Bioprocess Scale-Up from Lab Scale to Commercial GMP Manufacturing 

Clinical trials, GMP, Manufacturing
Navigating regulatory approval of biologics: A guide for emerging biotechs Bringing a biologic to market is an increasingly complex task, especially for small and mid-sized biotech companies with limited regulatory infrastructure. Meeting sometimes divergent EMA and FDA expectations, following increasingly complex regulations, and avoiding pitfalls related to documentation requires early planning and cooperation. Cross-functional alignment is also crucial to avoid issues related to comparability and process development/design space/process validation. This whitepaper outlines the key considerations in regulatory planning and biologics development, offering actionable insights for sponsors preparing their therapies for market. Bringing a biologic to market is a complex task, but with strategic planning and the right partners, emerging biotechs can overcome the regulatory hurdles with confidence. Mabion’s deep understanding of both EU and US regulatory requirements, coupled with extensive hands-on experience in biologics development and manufacturing, positions us as an ideal partner for companies seeking to streamline their path to approval.

Navigating Regulatory Approval of Biologics: A Guide for Emerging Biotechs

EMA, FDA, GMP, Regulatory
microbiological cleaning in cleanrooms

Microbiological Cleaning in Cleanrooms in CDMO Operation

GMP, Microbiology
1 2 Next

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • CDMO
    • Media kit
    • Press releases
    • Events

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. HTML Sitemap

    Powered by

    Veneo